(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
-4.24% $ 0.574
Live Chart Being Loaded With Signals
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine...
Stats | |
---|---|
Tagesvolumen | 183 338 |
Durchschnittsvolumen | 460 969 |
Marktkapitalisierung | 16.32M |
EPS | $0 ( 2024-04-01 ) |
Nächstes Ertragsdatum | ( $-0.530 ) 2024-05-20 |
Last Dividend | $0.250 ( 2012-04-02 ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.100 |
ATR14 | $0.00600 (1.05%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-07-27 | Dewilde Michel | Buy | 35 000 | Option (Right to Buy Common Shares) |
2023-07-27 | Braga Damian | Buy | 35 000 | Option (Right to Buy Common Shares) |
2023-07-27 | Baxter Jeff | Buy | 70 000 | Option (Right to Buy Common Shares) |
2023-07-27 | Cordeiro Joanne | Buy | 35 000 | Option (Right to Buy Common Shares) |
2023-07-27 | Beattie Nell | Buy | 52 500 | Option (Right to Buy Common Shares) |
INSIDER POWER |
---|
-68.18 |
Last 96 transactions |
Buy: 56 847 323 | Sell: 16 390 901 |
Volumen Korrelation
VBI Vaccines Inc Korrelation
10 Am meisten positiv korreliert | |
---|---|
KRON | 0.879 |
VTSI | 0.868 |
RUBY | 0.866 |
ALVR | 0.862 |
ICCC | 0.849 |
PSTV | 0.84 |
LSBK | 0.828 |
GREE | 0.827 |
POWW | 0.827 |
PAIC | 0.826 |
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
VBI Vaccines Inc Korrelation - Währung/Rohstoff
VBI Vaccines Inc Finanzdaten
Annual | 2023 |
Umsatz: | $8.68M |
Bruttogewinn: | $-5.82M (-66.98 %) |
EPS: | $-5.96 |
FY | 2023 |
Umsatz: | $8.68M |
Bruttogewinn: | $-5.82M (-66.98 %) |
EPS: | $-5.96 |
FY | 2022 |
Umsatz: | $1.08M |
Bruttogewinn: | $-10.19M (-942.14 %) |
EPS: | $-16.37 |
FY | 2021 |
Umsatz: | $631 000 |
Bruttogewinn: | $-10.14M (-1 606.81 %) |
EPS: | $-0.270 |
Financial Reports:
No articles found.
VBI Vaccines Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.250 | 2003-12-18 |
Last Dividend | $0.250 | 2012-04-02 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 3 | -- |
Total Paid Out | $1.250 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.23 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2003 | $0.250 | 14.60% |
2004 | $0 | 0.00% |
2005 | $0 | 0.00% |
2006 | $0.750 | 16.50% |
2007 | $0 | 0.00% |
2008 | $0 | 0.00% |
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0.250 | 0.02% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -11.81 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -1.179 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -5.05 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0.478 | 0.800 | -2.61 | -2.09 | [1 - 3] |
quickRatioTTM | 0.329 | 0.800 | -2.77 | -2.21 | [0.8 - 2.5] |
cashRatioTTM | 0.313 | 1.500 | 9.37 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.610 | -1.500 | 10.00 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -17.68 | 1.000 | -7.66 | -7.66 | [3 - 30] |
operatingCashFlowPerShareTTM | -2.51 | 2.00 | -0.838 | -1.676 | [0 - 30] |
freeCashFlowPerShareTTM | -2.55 | 2.00 | -1.275 | -2.55 | [0 - 20] |
debtEquityRatioTTM | 7.05 | -1.500 | 10.00 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | -0.496 | 1.000 | -10.00 | -10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -9.09 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -1.134 | 1.000 | -7.41 | -7.41 | [0.2 - 2] |
assetTurnoverTTM | 0.0998 | 0.800 | -2.67 | -2.13 | [0.5 - 2] |
Total Score | -4.67 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.134 | 1.000 | -0.115 | 0 | [1 - 100] |
returnOnEquityTTM | -5.05 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -2.55 | 2.00 | -0.850 | -2.55 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -2.51 | 2.00 | -0.838 | -1.676 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.00180 | 1.500 | -3.32 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -6.93 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.85 |
VBI Vaccines Inc
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.